3M announced today it has completed its acquisition of Arizant Inc., a leading manufacturer of patient warming solutions designed to prevent hypothermia in surgical settings.

Patient warming is a highly strategic adjacency for 3M and integral to infection prevention. Arizant expands 3M’s infection prevention offerings and will help to drive growth internationally.

Arizant, which was majority-owned by Court Square Capital since 2004, created the category of forced-air patient warming with the introduction of Bair Hugger^® therapy in 1987. Today, Arizant products help maintain normal body temperature, known as normothermia, in more than 20 million surgical patients annually as part of an effort to help prevent surgical site infections and other serious complications associated with surgical hypothermia.

3M’s infection prevention business helps hospitals reduce healthcare-associated infections. Its wide variety of products and systems for controlling the risk of infection includes applications for sterilization and monitoring, hand hygiene, perioperative preps, and surgical drapes.

About Arizant Inc.
Arizant, headquartered in Eden Prairie, Minn., is the maker of surgical patient temperature management systems including Bair Hugger^® therapy, the Bair Paws^® patient adjustable warming system, and the Ranger^® blood and fluid warming systems. Arizant created the category of forced-air warming, which is the preferred method of warming surgical patients in the U.S.

About Court Square Capital
Court Square Capital is one of the most experienced private equity firms in the industry. Since 1980, the group has invested in over 170 transactions across a wide array of sectors including: healthcare, aerospace & defense, industrials, business services, technology, media and travel. Court Square Capital currently manages over $4 billion of aggregate capital commitments and is based in New York, NY. For more information please refer to Court Square’s website at www.courtsquare.com

About 3M Infection Prevention
3M Infection Prevention Division is truly on a mission to help reduce healthcare-associated infections through its infection prevention solutions. With its system of people, products and processes, 3M remains a trusted partner committed to helping hospitals reduce the risk of infections, improve patient outcomes, and control their bottom lines. Learn more at www.3m.com/infectionprevention

About 3M
A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M’s core strength is applying its more than 40 distinct technology platforms – often in combination – to a wide array of customer needs. With $23 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 65 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.

Media Contacts:3MDonna Fleming Runyon, 651-736-7646orArizantTroy Bergstrom, 952-947-1214orInvestor Contacts:3MMatt Ginter, 651-733-8206orBruce Jermeland, 651-733-1807